Literature DB >> 29324432

An Overview of Clinical and Health Economic Evidence Regarding Porcine Small Intestine Submucosa Extracellular Matrix in the Management of Chronic Wounds and Burns.

Leo M Nherera1, Marco Romanelli2, Paul Trueman1, Valentina Dini3.   

Abstract

Small intestine submucosa (SIS) has been extensively evaluated in preclinical models and developed into commercially produced medical technologies intended for use in several different indications. The SIS extracellular matrix cellular and/or tissue-based product is a commercially available, porcine-derived SIS dressing. The purpose of this review was to consider the role of the SIS dressing in the management of chronic wounds and burns. Using a variety of search terms from the literature to describe the SIS dressing, the following databases were searched: PubMed, York Centre for Reviews and Dissemination database, National Health Service Economic Evaluation database, Health Technology Assessment database, and the Cochrane Library. The search identified 78 studies of which 21 met the inclusion/exclusion criteria. Of those, 14 involved chronic wounds, 3 described the management of burn wounds, and 4 were economic evaluations. The wide variety of comparative treatments and outcomes studied precluded the use of meta-analysis techniques. Study results show SIS dressings may improve outcomes in chronic wounds and cost less than several alternative biological wound treatments. Studies to examine their efficacy in burn wound management are warranted.

Mesh:

Year:  2017        PMID: 29324432

Source DB:  PubMed          Journal:  Ostomy Wound Manage        ISSN: 0889-5899            Impact factor:   2.629


  4 in total

1.  Case Report: Biologic graft placement with subsequent radiation therapy following radical vulvectomy for adenoid cystic carcinoma of the Bartholin's gland.

Authors:  Keely Ulmer; Megan E McDonald; Joseph T Kowalski
Journal:  Gynecol Oncol Rep       Date:  2021-02-27

Review 2.  Decellularized extracellular matrix mediates tissue construction and regeneration.

Authors:  Chuanqi Liu; Ming Pei; Qingfeng Li; Yuanyuan Zhang
Journal:  Front Med       Date:  2021-12-28       Impact factor: 4.592

3.  Use of a purified reconstituted bilayer matrix in the management of chronic diabetic foot ulcers improves patient outcomes vs standard of care: Results of a prospective randomised controlled multi-centre clinical trial.

Authors:  David G Armstrong; Dennis P Orgill; Robert D Galiano; Paul M Glat; Jarrod P Kaufman; Marissa J Carter; Lawrence A DiDomenico; Charles M Zelen
Journal:  Int Wound J       Date:  2022-01-09       Impact factor: 3.099

4.  Comment on "An observational pilot study using a purified reconstituted bilayer matrix to treat non-healing diabetic foot ulcers".

Authors:  Adam L Isaac; Michael Tritto
Journal:  Int Wound J       Date:  2020-10-22       Impact factor: 3.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.